CHMP Recommends Caprelsa Approval in EU on Condition AstraZeneca Conducts PGx Trial
November 30, 2011
CHMP Recommends Caprelsa Approval in EU on Condition AstraZeneca Conducts PGx Trial
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Stanford Spinout NuMedii Seeks Pharma Partners to Use PGx Repositioning Algorithm in Drug Pipelines
August 24, 2011 / Pharmacogenomics Reporter - Pfizer Using Qiagen KRAS Test to Study Dacomitinib Head-to-Head Against Tarceva in NSCLC
August 17, 2011 / Pharmacogenomics Reporter - Boehringer Launches 'Let's Test' Campaign to Educate Healthcare Providers on NSCLC Biomarker Testing
October 24, 2012 / Pharmacogenomics Reporter - After FDA Letter Seeking More Data, Lilly Won't Pursue CDx-Guided Erbitux in NSCLC in the US
May 2, 2012 / Pharmacogenomics Reporter